By searching for the Canadian Licensed Natural Health Products Database, (LNHPD), this paper analyzed the characteristics and current status of 92 Chinese patent medicines successfully registered and listed in Canada, and found that the enterprises of successfully registered enterprises are mainly located in areas with better development condition of Traditional Chinese Medicine (TCM) such as Beijing, Guangdong and Tianjin; The successfully registered Chinese patent medicines include 64 kinds of single medicine or medicine with single active ingredient (69.6%) and 28 kinds of compound medicine (30.4%), the forms of the dosage are mainly tablets and capsules, which have the characteristics of accuracy in dosage and stable physicochemical properties. There are also granules, solutions, powders and other dosage forms, which can be preserved for a long time and have low requirements on technic and environment. These Chinese patent medicines are mainly used to treat respiratory and circulatory system diseases, some are used to treat urogenital and digestive system diseases, and few are used to treat difficuilt diseases like tumors, diabetes. There are some other health care products. It is suggested to strengthen the connection between domestic standards of TCM registration and international standards, and promote the scientific and technological capacity of relevant enterprises, and encourage enterprises to strengthen international registration of advantageous products, so as to accelerate the speed of international development of TCM in China.

The paper introduces the application technology of whole process medical insurance informatization management in the Third Hospital Affiliated to Sun Yat-sen University,including how to implement the medical insurance information into the whole treatment process in real time,construct the medical insurance database suitable for the hospital and interface technology of medical insurance settlement,so as to lay foundation to achieve disease diagnosis related groups.

BACKGROUNDDrug-eluting stents (DES) with durable polymer have significantly reduced restenosis and target vessel revascularization compared with bare metal stents. Durable polymer has been linked with persistent inflammation of vessel wall and delayed endothelial healing that may increase the risk of late and very late stent thrombosis. This study sought to evaluate the efficacy and safety of HELIOS completed biodegradable polymer sirolimus-eluting stent (SES) in de novo coronary lesions.

METHODSTotally, 287 patients with one or two de novo coronary lesions (lesion length ≤ 38 mm and reference vessel diameter 2.5-4.0 mm) were enrolled in the HOPE study, a prospective, multicenter, randomized, non-inferiority trial. Patients were randomized to treatment either with HELIOS completed biodegradable polymer SES (n = 142) or PARTNER durable polymer SES (n = 145). The primary endpoint was angiographic in-stent late lumen loss (LLL) at 9-month follow-up. The secondary endpoint included stent thrombosis and major adverse cardiac events including cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR).

RESULTSThe 9-month in-stent LLL in the HELIOS group was similar to the PARTNER group, (0.16 ± 0.22) mm vs. (0.19 ± 0.30) mm (P = 0.28). The difference and 95% confidence interval were -0.03 (-0.09, 0.04), and the P value for non-inferiority <0.01. Major adverse cardiovascular event (MACE) occurred in 7.9% vs. 8.2%, MI in 2.4% vs. 3.0%, TLR in 5.5% vs. 3.0%, and stent thrombosis in 0 vs. 1.5%; and events were comparable between the HELIOS group and PARTNER group at three-year follow-up (all P > 0.05). The three-year cardiac death was lower in the HELIOS group, but with no significant difference, 0 vs. 3.0% (P = 0.12).

CONCLUSIONSIn the HOPE trial, the novel completed biodegradable polymer SES HELIOS was non-inferior to the durable polymer SES PARTNER with respect to nine-month in-stent LLL in de novo coronary lesions. The incidence of other clinical endpoints was low for both of the stents in three-year follow-up.

Adult ; Aged ; Angiography ; Coronary Artery Disease ; surgery ; Coronary Restenosis ; prevention & control ; Drug-Eluting Stents ; Humans ; Middle Aged ; Percutaneous Coronary Intervention ; Polymers ; chemistry ; therapeutic use ; Sirolimus ; therapeutic use ; Titanium ; chemistry ; Treatment Outcome ; Young Adult

BACKGROUNDFirst generation drug-eluting stents (DES) were associated with a high incidence of late stent thrombosis (ST), mainly due to delayed healing and re-endothelization by the durable polymer coating. This study sought to assess the safety and efficacy of the Nano polymer-free sirolimus-eluting stent (SES) in the treatment of patients with de novo coronary artery lesions.

METHODSThe Nano trial is the first randomized trial designed to compare the safety and efficacy of the Nano polymer-free SES and Partner durable-polymer SES (Lepu Medical Technology, Beijing, China) in the treatment of patients with de novo native coronary lesions. The primary endpoint was in-stent late lumen loss (LLL) at 9-month follow-up. The secondary endpoint was major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction or target lesion revascularization.

RESULTSA total of 291 patients (Nano group: n = 143, Partner group: n = 148) were enrolled in this trial from 19 Chinese centers. The Nano polymer-free SES was non-inferior to the Partner durable-polymer DES at the primary endpoint of 9 months (P < 0.001). The 9-month in-segment LLL of the polymer-free Nano SES was comparable to the Partner SES (0.34 ± 0.42) mm vs. (0.30 ± 0.48) mm, P = 0.21). The incidence of MACE in the Nano group were 7.6% compared to the Partner group of 5.9% (P = 0.75) at 2 years follow-up. The frequency of cardiac death and stent thrombosis was low for both Nano and Partner SES (0.8% vs. 0.7%, 0.8% vs. 1.5%, both P = 1.00).

CONCLUSIONSIn this multicenter randomized Nano trial, the Nano polymer-free SES showed similar safety and efficacy compared with the Partner SES in the treatment of patients with de novo coronary artery lesions. Trials in patients with complex lesions and longer term follow-up are necessary to confirm the clinical performance of this novel Nano polymer-free SES.

Aged ; Coronary Artery Disease ; drug therapy ; surgery ; Drug-Eluting Stents ; Female ; Humans ; Immunosuppressive Agents ; therapeutic use ; Male ; Middle Aged ; Prospective Studies ; Sirolimus ; therapeutic use

OBJECTIVE: To study the cytotoxicity of recombinate toxin MSH-Ang to Hep-2. METHOD: The depurated MSH-Ang were applied in cytotoxicity experiment, and the growth inhibiting action to laryngeal carcinoma cell Hep-2 were observed. RESULT: Recombination protein inhibited the growth of laryngeal carcinoma cell Hep-2, and its inhibiting action enhanced and corpuscular mortality rate increased along with the concentration increasing. CONCLUSION Recombinant toxin MSH-Ang can not only take special effect in tumors with high MSHR, but also target to many other popular tumors.
Angiopoietins ; genetics ; pharmacology ; Cell Line, Tumor ; Genetic Engineering ; Humans ; Laryngeal Neoplasms ; Melanocyte-Stimulating Hormones ; genetics ; pharmacology ; Recombination, Genetic

OBJECTIVE: To observe the feasibility and effect of improved standard facial translocation approach in treating anterior-lateral benign tumor in middle cranial fossa base. METHOD: We excised 10 cases of benign tumor originating from pharynx nasals of pterygopalatine fossa and expanding toward the cavernous sinus of middle cranial fossa, infratemporal fossa or pterygo-maxillary space. We ameliorated, facial incision, maxilla disassembled, reestablishment, fixation,maxillary mucosal option and remained lateral wall of nasal cavity to some extent. RESULT: The mean time of following-up was 38 month postoperatively without complications of bleeding, infection and necrosis or prolapse of displacing bones. Nine patients were treated successfully, one died. CONCLUSION Reforming facial translocation approach in treating anterior-lateral benign tumor in middle cranial fossa base was safe and obtained ideal curative effect in near future.
Adolescent ; Adult ; Aged ; Cranial Fossa, Middle ; pathology ; surgery ; Craniotomy ; methods ; Female ; Humans ; Male ; Middle Aged ; Skull Base Neoplasms ; pathology ; surgery ; Treatment Outcome ; Young Adult

OBJECTIVE: To detect expression level and distribution of aquaporin 1 (AQP1) in laryngeal carcinoma tissues and try to find out the significance about the mechanism of AQP1 in the invasion of laryngeal carcinoma. METHOD: Twenty cases of laryngeal carcinoma tissues and 15 cases of normal tissues beside tumors were acquired immediately after surgery. The expression and distribution of aquaporin 1 in laryngeal carcinoma were examined by RT-PCR, western blot analysis and immunohistochemical technique. RESULT: AQP1 expresses on the capillary endothelia of laryngeal mucous lamina propria and laryngeal mucous glands of normal tissues and mainly on the capillary endothelia cells, tumor cells and cancer nests of laryngeal carcinoma tissues. AQP1 mRNA and protein expression level in laryngeal tumor tissues is remarkably stronger than that in normal tissues beside tumors. CONCLUSION The expression of AQP1 was increased in laryngeal carcinoma tissues over normal laryngeal tissues. It suggests that the mechanism of AQP1 in laryngeal carcinoma etiopathogenesis needs to be studied.
Adult ; Aged ; Aquaporin 1 ; metabolism ; Carcinoma, Squamous Cell ; blood supply ; metabolism ; pathology ; Case-Control Studies ; Female ; Humans ; Laryngeal Neoplasms ; blood supply ; metabolism ; pathology ; Male ; Middle Aged ; Neoplasm Staging

OBJECTIVE: To investigate the efficacy and the value of CAUP in treatment of OSAHS. METHOD: CAUP and the dissection of palatopharyngeus muscle were performed by RFVTR . One hundred and sixty-eight patients with OSAHS treated by CAUP from July 2001 to July 2004 were summarized. Among them, 52 patients were analyzed by PSG after 1 year of the operation. RESULT: All the operative procedure were carried out smoothly with excellent patient tolerance. Post-operation complications were foreign body feeling in oral cavity. No velopalatal insufficiency occurred. The efficient rate was 94.2% after 1 year of the operation according to the PSG results. CONCLUSION CAUP is a simple, safe,repeatable and acceptable surgical procedure and it was developing with excellent value in the treatment of OSAHS on the basic of accurate X-ray imaging.
Adult ; Aged ; Catheter Ablation ; methods ; Female ; Humans ; Male ; Middle Aged ; Palate, Soft ; surgery ; Palatine Tonsil ; surgery ; Sleep Apnea, Obstructive ; surgery ; Tongue ; surgery ; Turbinates ; surgery ; Uvula ; surgery ; Young Adult

OBJECTIVETo explore the response of nasal mucosa epithelial cells to hypoxia in terms of formation of nasal polyps (NP).

METHODSEpithelial cells of NP and inferior turbinate (IT) were cultured serum-free under normal oxygen and hypoxic circumstances with stimulation of IL-1 beta and TNF alpha. The vascular endothelial growth factor (VEGF) mRNA and VEGF protein levels of the cultured cells were detected using in situ hybridization and ELISA, respectively.

RESULTSThe expression of VEGF mRNA was significantly higher in epithelial cells of NP than in IT exposed to pro-inflammatory cytokines or hypoxia (P < 0.01). VEGF levels were higher in NP epithelial cells than those of IT (P < 0.01) under hypoxia.

CONCLUSIONVEGF-induced by hypoxia is very important for the early stages of forming polyps.

Cell Hypoxia ; physiology ; Cells, Cultured ; Endothelial Growth Factors ; genetics ; Enzyme-Linked Immunosorbent Assay ; Erythropoietin ; genetics ; Humans ; Intercellular Signaling Peptides and Proteins ; genetics ; Interleukin-1 ; pharmacology ; Lymphokines ; genetics ; Nasal Mucosa ; metabolism ; Nasal Polyps ; etiology ; metabolism ; RNA, Messenger ; analysis ; Tumor Necrosis Factor-alpha ; pharmacology ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors

OBJECTIVETo explore the significance of protein kinase C (PKC) in proliferation and infiltration of eosinophils in nasal polyps.

METHODSWith in situ hybridization and immunohistochemistry staining methods, PKC, pro-apoptotic, and anti-apoptotic gene (Bax, bcl-2) expressions were measured in nasal polyp tissues from 26 patients and inferior turbinate mucosa tissues (ITMTs) from 20 healthy persons. The May-Grünwald-Giemsa (MGG) staining method was used to identify eosinophils.

RESULTSIn eosinophils, the positive cell expressive rates of Bcl-2 mRNA and its protein were significantly higher in the group with nasal polyps than in the ITMT group (P < 0.01). Although the positive cell expressive rate of Bax mRNA and associated protein were a little higher in the group with nasal polyp tissues than in the ITMT group, the difference was not significant (P > 0.05). There was PKC expression in the eosinophils of 26 cases of nasal polyps, but occasional PKC expression in 7 of 20 ITMT cases. In the two groups, PKC positive cell expression was significantly different, and the expression of PKC and bcl-2 mRNA as well as associated protein in eosinophils of nasal polyps showed a remarkably positive relationship (r1 = 0.0875, r2 = 0.0823, P < 0.01).

CONCLUSIONSIncreased PKC expression in eosinophils of nasal polyp tissues is closely associated with apoptosis inhibition, and it is presumed that eosinophil apoptosis inhibition in nasal polyp tissues is obtained by activation of the PKC signal transduction pathway.

Adult ; Aged ; Cell Division ; Eosinophils ; enzymology ; pathology ; Female ; Humans ; Male ; Middle Aged ; Nasal Polyps ; enzymology ; pathology ; Protein Kinase C ; analysis ; Signal Transduction ; physiology